Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you

recruiting
3 979
countries
28
conditions
2 106

38 trials match your criteria

Axial spondyloarthritis+3

Recruiting

Study of Janus kinase inhibitor dose reduction in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis who have achieved low disease activity

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Baricitinib

Axial spondyloarthritis+1

Recruiting

Study on the Effects of Upadacitinib for Patients with Active Psoriatic Arthritis and Axial Spondyloarthritis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib

Rheumatic disorder

Recruiting

Study on Immune Response to Recombinant Zoster Vaccine in Rheumatic Disease Patients Using Baricitinib, Tofacitinib, or Methotrexate

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Baricitinib

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of Vedolizumab and Upadacitinib in Adults with Moderate to Severe Crohn's Disease

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib

Dermatomyositis+4

Recruiting

Study on Upadacitinib for Patients with Idiopathic Inflammatory Myopathies After Stopping IVIG

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Upadacitinib

Rheumatoid arthritis

Recruiting

Study on Reducing JAK Inhibitor Doses in Patients with Low Disease Activity in Rheumatoid Arthritis Using Tofacitinib and Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Baricitinib

Crohn's disease

Recruiting

Study on Transmural Healing in Patients with Moderate to Severe Crohn's Disease Using Upadacitinib and Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab

Psoriatic arthropathy

Recruiting

Study on Reducing Immunosuppressive Drugs in Adults with Psoriatic Arthritis: Methotrexate Disodium, Abatacept, and Certolizumab Pegol

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abatacept

Juvenile idiopathic arthritis

Recruiting

Study on Upadacitinib and Tocilizumab for Children and Teens with Active Systemic Juvenile Idiopathic Arthritis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Tocilizumab

Dermatitis atopic

Recruiting

Study on Atopic Dermatitis Treatment with Baricitinib, Tralokinumab, Abrocitinib, Upadacitinib, and Dupilumab for Patients Needing Second-Line Systemic Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Abrocitinib

Rheumatoid arthritis

Recruiting

Study Comparing Methotrexate or Leflunomide with Targeted Therapy vs. Methotrexate or Leflunomide with Drug Combination for Rheumatoid Arthritis Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abatacept

Giant cell arteritis

Not yet recruiting

Efficacy of upadacitinib plus short prednisolone tapering in adults with Giant Cell Arteritis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lactose Monohydrate

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.